Pillstats
Rx only · Tablet, Film Coated · Oral

Tazemetostat

Brands: Tazverik · Tazemetostat Hydrobromide

0 ACTIVE SUPPLIERS — US
openFDA · updated weekly
US1 NDCs
0 active makers
UKComing
soon
CAComing
soon
AUComing
soon
EUComing
soon
ATC—
RxCUI (US)—
US makers1 labelers
Packages1
DEA / ScheduleNone

Medicaid dispensing volumeSDUD · per quarter

Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume — Medicaid only, not all-payer.

244973982025 Q12025 Q22025 Q32025 Q42026 Q1
42
Rx · 2026 Q1
8.4K
Units dispensed
-51%
Rx vs. year ago
5
Quarters · since 2025 Q1

Who makes it0 active · 1 exited

US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.

LabelerTypePackagesStatus
Epizyme, Inc.unknown1EXITED 2029

Regulatory & supply eventsFDA · US

Shortages, recalls, and registration changes attached to this drug concept.

  • Mar 27, 2026
    RESOLVEDShortage resolved: Tazemetostat Hydrobromide Tablet (Epizyme, Inc. (An Ipsen Company))

    Tazemetostat Hydrobromide Tablet — reported in shortage by Epizyme, Inc. (An Ipsen Company). Therapeutic category: Oncology.

  • Mar 27, 2026
    SHORTAGEDrug shortage: Tazemetostat Hydrobromide Tablet (Epizyme, Inc. (An Ipsen Company))

    Tazemetostat Hydrobromide Tablet — reported in shortage by Epizyme, Inc. (An Ipsen Company). Therapeutic category: Oncology.